HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism

Address correspondence and reprint requests to Dr. Kenneth Marek, Department of Neurology, Yale University School of Medicine, 40 Temple St/Suite 6C, New Haven, CT 06510; e-mail: Ken.Marek{at}yale.edu

BACKGROUND: In vivo imaging of the dopamine transporter (DAT) with SPECT is a quantitative biomarker for PD onset and severity.

OBJECTIVE: To use a multicenter study to evaluate the diagnostic accuracy of DOPASCAN and SPECT in patients with PD, progressive supranuclear palsy (PSP), and essential tremor (ET), and in healthy controls (HC).

METHODS: Ninety-six individuals with known clinical diagnosis were imaged with DOPASCAN at five sites with different multidetector SPECT systems. Both masked visual interpretation and region of interest (ROI) analysis were performed at each site and at a core analysis center.

RESULTS: Visual interpretation of the images by an expert panel demonstrated a sensitivity of 0.98 and specificity of 0.83 comparing parkinsonian (PD + PSP) versus nonparkinsonian (ET + HC) controls. Quantitative analysis of putamen and caudate DOPASCAN uptake for each region in the PD or PSP groups was significantly reduced compared to the ET or HC groups. Comparison of parkinsonian (PD + PSP) versus nonparkinsonian (ET + HC) individuals demonstrated a reduction of 76% in mean putamen and 48% in mean caudate DOPASCAN uptake.

CONCLUSIONS: DOPASCAN and SPECT imaging reliably and effectively distinguish between subjects with Parkinson’s syndrome (PD + PSP) and without Parkinson’s syndrome (HC + ET). This is the first multicenter assessment of dopamine transporter imaging demonstrating that this tool may be used widely to assess dopaminergic degeneration in patients with parkinsonism.–1547

This article has been cited by other articles:

				C. W. Olanow, M. B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136. [Abstract] [Full Text] [PDF]

				I. G. Zubal, M. Early, O. Yuan, D. Jennings, K. Marek, and J. P. Seibyl Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients J. Nucl. Med., June 1, 2007; 48(6): 857 - 864. [Abstract] [Full Text] [PDF]

				K. Van Laere, C. Casteels, L. De Ceuninck, B. Vanbilloen, A. Maes, L. Mortelmans, W. Vandenberghe, A. Verbruggen, and R. Dom Dual-Tracer Dopamine Transporter and Perfusion SPECT in Differential Diagnosis of Parkinsonism Using Template-Based Discriminant Analysis J. Nucl. Med., March 1, 2006; 47(3): 384 - 392. [Abstract] [Full Text] [PDF]

				V. L. Marshall, D. G. Grosset, R. M. Zweig, D. L. Lilien, K. Tainter, J. Patterson, B.M. Ravina, N. Lange, K. Marek, R. Holloway, et al. The role of radiotracer imaging in Parkinson disease Neurology, October 11, 2005; 65(7): 1144 - 1145. [Full Text] [PDF]

				B. Ravina, D. Eidelberg, J. E. Ahlskog, R. L. Albin, D. J. Brooks, M. Carbon, V. Dhawan, A. Feigin, S. Fahn, M. Guttman, et al. The role of radiotracer imaging in Parkinson disease Neurology, January 25, 2005; 64(2): 208 - 215. [Abstract] [Full Text] [PDF]

				S. Colloby and J. O'Brien Functional Imaging in Parkinson's Disease and Dementia with Lewy Bodies J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 158 - 163. [Abstract] [PDF]

				W. J. Hwang, W. J. Yao, S. P. Wey, and G. Ting Reproducibility of 99mTc-TRODAT-1 SPECT Measurement of Dopamine Transporters in Parkinson's Disease J. Nucl. Med., February 1, 2004; 45(2): 207 - 213. [Abstract] [Full Text] [PDF]

				W.-S. Huang, Y.-H. Chiang, J.-C. Lin, Y.-H. Chou, C.-Y. Cheng, and R.-S. Liu Crossover Study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's Disease Patients J. Nucl. Med., July 1, 2003; 44(7): 999 - 1005. [Abstract] [Full Text] [PDF]

				N. Quinn and P. S. Group A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism Neurology, August 28, 2001; 57(4): 746 - 747. [Full Text] [PDF]

Correspondence: